Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Biotechnology company MabCure, Inc. is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists.

9 Mar 2011

Overall survival rate for ovarian cancer have increased over last 30 years

Survival from ovarian cancer has almost doubled over the last 30 years according to new figures from Cancer Research UK released today.

9 Mar 2011

Caris Life Sciences to highlight new approaches for gynecologic cancers at SGO 2011 conference

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from the company's upcoming symposium, "Using Biomarker Expression to Guide Therapy: An Evidence-Based Approach for Gynecologic Cancers," at the Society of Gynecologic Oncologists 2011 Annual Meeting on Women's Cancer in Orlando, FL on March 6.

5 Mar 2011

Study reports highest rate of exclusive breastfeeding in El Camino Women's Hospital

The Women's Hospital at El Camino Hospital had the highest rate of exclusive and partial breastfeeding by new mothers of any hospital in the state for 2009, according to a study recently released by the UC-Davis Human Lactation Center and the California WIC Association.

5 Mar 2011

Scientist receives $4 million Australia fellowship to continue cancer origin research

Walter and Eliza Hall Institute cancer researcher Professor Jane Visvader has received a $4 million fellowship from the Australian Government to continue her work into the origin of breast, ovarian and lung cancers.

3 Mar 2011

Genetics and cancer research

The 20th century was dominated by breakthroughs in physics and chemistry, but the 21st century will belong to genetics and biotechnology. Cancer research is just one area among many that is being transformed by the sequencing of the human genome. This was one of the topics discussed in our recent panel with leading cancer researchers, part of our Breakthroughs: Cancer series.

3 Mar 2011

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

3 Mar 2011

Research: Blocking two cell DNA repair routes at once can provide new way to treat bowel cancer

Cancer Research UK-funded scientists have discovered that blocking two cell DNA repair routes at once could provide a completely new way to treat bowel cancer and potentially other cancers, according to research published in Cancer Research, today.

2 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

SPIN program to help mothers produce sufficient breast milk for their premature infants

Approximately 50,000 premature babies weighing less than three pounds are born in the United States each year. These fragile newborns need the highest quality nutrition, which is why UC San Diego Health System developed the Supporting Premature Infant Nutrition program to help mothers produce sufficient breast milk for their premature infants.

24 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

Biologist investigates CAPV-EAE population for hereditary breast and ovary cancer

Between 5 % and 10 % of breast cancer cases are hereditary, arising because the patient inherits from the father or mother a mutation in a gene that is susceptible to causing the illness. BRCA1 and BRCA2 have already been identified as two of the genes to be monitored. It is estimated that 30 % of hereditary breast cancer cases are due to mutations in one of these two genes.

19 Feb 2011

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Australian health care company Prima BioMed Ltd announced today that there has been an agreement for strategy and design of the Phase III clinical registration trial for the CVac™ immunotherapy therapeutic ovarian cancer vaccine.

19 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

BD and UCLB enter agreement for development of new diagnostics for ovarian, breast cancer

UCL Business (UCLB), a wholly owned subsidiary of University College London (UCL), and BD (Becton, Dickinson and Company), a leading global medical technology company, announced today an agreement aimed at improving the early detection of ovarian and breast cancers to ultimately enable earlier and more effective treatment.

From BD (Becton, Dickinson and Company) 10 Feb 2011

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis.

9 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Patients receiving cancer treatment may experience skin, hair, nail problems

A cancer diagnosis and subsequent treatment, which commonly includes chemotherapy or radiation, can be taxing physically and emotionally on any patient. If that is not enough, dermatologists are cautioning patients receiving cancer treatment and cancer survivors that they may experience a host of skin, hair or nail problems as a direct result of their therapy that may require additional treatment by a dermatologist.

5 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Overall survival rate for ovarian cancer have increased over last 30 years

Caris Life Sciences to highlight new approaches for gynecologic cancers at SGO 2011 conference

Study reports highest rate of exclusive breastfeeding in El Camino Women's Hospital

Scientist receives $4 million Australia fellowship to continue cancer origin research

Genetics and cancer research

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

Research: Blocking two cell DNA repair routes at once can provide new way to treat bowel cancer

TCD announces first patient treated in its TCD-717 Phase I trial

SPIN program to help mothers produce sufficient breast milk for their premature infants

Cannabis Science extract treatments help kill cancer cells

Biologist investigates CAPV-EAE population for hereditary breast and ovary cancer

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

BD and UCLB enter agreement for development of new diagnostics for ovarian, breast cancer

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Patients receiving cancer treatment may experience skin, hair, nail problems

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Merck reports GAAP net income of $861 million for 2010

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in